loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X

Approved Drug Products containing 65003 listed in the FDA Orange Book. Original Data : FDA Website

Client Virtual Booth
Menu
Filters Filter
Cross PopUp
FILTER :

filter

01 ABBVIE (3)

filter

01 CAPSULE;ORAL (3)

filter

01 DISCN (1)

02 RX (2)

filter

01 GENGRAF (3)

filter

01 No (3)

URL Supplier Web Content
CAPSULE; ORAL
100MG
2000-05-12
65003
GENGRAF
RX
No
AB1
Abbvie Company Banner

RDD 2024

Not Confirmed

envelop Contact Supplier
URL Supplier Web Content
CAPSULE; ORAL
25MG
2000-05-12
65003
GENGRAF
RX
No
AB1
Abbvie Company Banner

RDD 2024

Not Confirmed

envelop Contact Supplier
URL Supplier Web Content
CAPSULE; ORAL
50MG
2000-05-12
65003
GENGRAF
DISCN
No
Abbvie Company Banner

RDD 2024

Not Confirmed

envelop Contact Supplier

Looking for FDA Orange Book APPLICATION 65003

Looking for FDA Orange Book APPLICATION 65003 3

19

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is CYCLOSPORINE, with a corresponding application number 65003.

Regulatory Information RX

With a dosage strength 100MG

Dosage Form Route CAPSULE; ORAL

Reference Listed Drug No

Approved since 2000-05-12

Therapeutic Equivalence (TE) Code AB1

18

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is CYCLOSPORINE, with a corresponding application number 65003.

Regulatory Information RX

With a dosage strength 25MG

Dosage Form Route CAPSULE; ORAL

Reference Listed Drug No

Approved since 2000-05-12

Therapeutic Equivalence (TE) Code AB1

17

AbbVie Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

One of their notable products is CYCLOSPORINE, with a corresponding application number 65003.

Regulatory Information DISCN

With a dosage strength 50MG

Dosage Form Route CAPSULE; ORAL

Reference Listed Drug No

Approved since 2000-05-12

Post Enquiry
POST ENQUIRY